Core Viewpoint - Zealand Pharma A/S has reported the total number of shares and voting rights as of December 31, 2025, following a share capital increase due to the exercise of employee warrants [1][2]. Group 1: Share Capital and Voting Rights - As of December 31, 2025, Zealand Pharma has a total of 71,515,045 shares, with a nominal value of DKK 1 each, resulting in a share capital of DKK 71,515,045 and an equal number of voting rights [3]. Group 2: Company Overview - Zealand Pharma A/S is a biotechnology company focused on developing medicines for obesity and metabolic health, leveraging over 25 years of peptide R&D expertise and advanced data-driven approaches [4]. - The company has more than ten drug candidates that have entered clinical development, with two products already on the market and three candidates in late-stage development [4]. - Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in Boston, Massachusetts [4].